Regeneron Pharmaceuticals, Inc. REGN

NASDAQ · Healthcare · Biotechnology

$920.69

Close on Fri, 20 Nov 2026 · market value $95.2B

What the price is betting on

Below its record

At $921, the price assumes revenue grows about 0% a year for five years, from $16.9B to about $16.9B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.

The price assumes0%
Analysts, next two years12%
Last 3 years9.6%

Revenue growth a year. The price figure comes from a reverse DCF at a 6.5% discount rate.

Track it and Parra checks each report against the path, and tells you when revenue falls behind it.

Own more than REGN? Check up to 5 of your stocks at once, free, no account.

0$10B$20B$30B$16.9B'22'23'24'25Sep '26'26'27'28'29'30What the price needsReportedAnalysts

Both sides

Three stories, three values

Bear

$1,312

Base

$1,661

Bull

$2,099

Today $921

  • Bear $1,312. Cash flow grows 6% a year for the next 5 years, slower than expected, then slows to long-run growth.
  • Base $1,661. Cash flow grows 11% a year for the next 5 years, as analysts expect, then slows to long-run growth.
  • Bull $2,099. Cash flow grows 15% a year for the next 5 years, faster than expected, then slows to long-run growth.

Stories set by rules from the company’s record.

Checkpoints

The revenue the price needs

  1. YearNeedsAnalysts expect
  2. FY2026$16.9B$18.8B, on the path
  3. FY2027$16.9B$20.1B, on the path
  4. FY2028$16.9B$21.6B, on the path
  5. FY2029$16.9B$23.3B, on the path
  6. FY2030$16.9B$24.8B, on the path

Each year's revenue at 0% growth from $16.9B in the 12 months to September 2026.

At a glance

Healthcare · Biotechnology · listed on NASDAQ

Revenue, FY2025
$14.3B
Growth, 3 years a year
9.6%
Cash margin
28%
Net cash
$5.9B
Shares, 3-year change
−4.3%
Dividend yield
0.4%

What other healthcare prices are betting on

Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.